Healthcare · Biotechnology
Price
$3.01
Market Cap
$48.3M
Employees
210
Beta
-1.13
Avg Volume
1,889,588
CEO
Mitchell S. Steiner
Business Description
Veru Inc. operates as a biopharmaceutical firm primarily dedicated to advancing novel therapeutic agents for various types of cancer. Commercially, Veru markets the FC2 internal condom, designed to offer dual protection against both unplanned pregnancies and the transmission of sexually transmitted infections. This product is distributed globally to a diverse clientele, including governmental health departments, UN organizations, non-profit entities, and commercial distributors. Its robust development pipeline features a range of investigational therapies, notably within oncology: Enobosarm, an orally administered selective androgen receptor agonist, is progressing through Phase III clinical trials for treating metastatic breast cancer that is AR+, ER+, and HER2-negative. Sabizabulin is undergoing Phase IIb studies for the same type of metastatic breast cancer. Furthermore, a combination therapy of Enobosarm with abemaciclib is in Phase III for AR+ ER+ HER2- metastatic breast cancer. For metastatic triple-negative breast cancer, Veru is exploring a combination of Sabizabulin (an oral targeted cytoskeleton disruptor) and Enobosarm (a selective androgen receptor agonist) in Phase II trials. The company's portfolio also extends to prostate cancer: Sabizabulin is in Phase II trials for metastatic castration and androgen receptor targeting agent-resistant prostate cancer. VERU-100, a GnRH antagonist peptide delivered via injection, is also in Phase II for advanced hormone-sensitive prostate cancer. Beyond oncology, Veru is investigating other conditions: Zuclomiphene Citrate is in Phase II for managing hot flashes. Sabizabulin has reached Phase III for treating SARS-CoV-2 in high-risk patients susceptible to acute respiratory distress syndrome. Additionally, the firm is developing a novel pharmaceutical formulation aimed at alleviating lower urinary tract symptoms associated with an enlarged prostate in men. Originally established as The Female Health Company in 1971, the corporation adopted the name Veru Inc. in July 2017. Its corporate headquarters are situated in Miami, Florida.
Business History
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-2.81
Stock Price: $3.01
EPS (Diluted): -1.07
EPS (Diluted): -1.07
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
3.04
Stock Price: $3.01
Total Equity: $18.33M
Shares: 14,646,294
Total Equity: $18.33M
Shares: 14,646,294
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-0.84
Market Cap: $48.31M
Total Debt: $758,946
Cash: $15.79M
EBITDA: -$35.38M
Total Debt: $758,946
Cash: $15.79M
EBITDA: -$35.38M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$43.0M
Market Cap: $48.31M
Total Debt: $758,946
Cash: $15.79M
Total Debt: $758,946
Cash: $15.79M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.00
Stock Price: $3.01
Revenue: $0.00
Shares: 14,646,294
Revenue: $0.00
Shares: 14,646,294
EV/Sales (Total value vs revenue — works when P/E can't)
API0.00
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: -$152,105
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$24.75M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$22.73M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-52.9%
Net Income: -$22.73M
Total Equity: $18.33M
Total Equity: $18.33M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-49.5%
Operating Income: -$24.75M
Tax Rate: 0.0%
Equity: $18.33M
Total Debt: $758,946
Cash: $15.79M
Tax Rate: 0.0%
Equity: $18.33M
Total Debt: $758,946
Cash: $15.79M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
2.43
Current Assets: $18.92M
Current Liabilities: $7.79M
Current Liabilities: $7.79M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.04
Short-Term Debt: $758,946
Long-Term Debt: $0.00
Total Debt: $758,946
Total Equity: $18.33M
Long-Term Debt: $0.00
Total Debt: $758,946
Total Equity: $18.33M
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 14,646,294
Shares: 14,646,294
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$1.25
Total Equity: $18.33M
Shares: 14,646,294
Shares: 14,646,294
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-2.05
Operating CF: -$30.04M
CapEx: -$1,083
Shares: 14,646,294
CapEx: -$1,083
Shares: 14,646,294
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $3.01
Stock Price: $3.01
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$22.73M
Net Income: -$22.73M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares VERU against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 24, 2026 5:24am (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $61.3M | $39.4M | $16.3M | $16.9M | $0 |
| Cost of Revenue | $13.3M | $8.8M | $8.7M | $11.0M | $152,105 |
| Gross Profit | $47.9M | $30.6M | $7.6M | $5.9M | $-152,105 |
| Operating Expenses | $53.4M | $113.8M | $101.3M | $42.8M | $24.8M |
| Operating Income | $13.0M | -$83.2M | -$93.8M | -$36.9M | -$24.8M |
| Net Income | $7.4M | -$83.8M | -$93.2M | -$37.8M | -$22.7M |
| EBITDA | $9.7M | -$79.2M | -$90.0M | -$36.2M | -$35.4M |
| EPS | $0.97 | $-10.49 | $-10.96 | $-2.80 | $-1.07 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 24, 2026 5:24am (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $122.4M | $80.2M | $9.6M | $24.9M | $15.8M |
| Total Current Assets | $151.8M | $104.0M | $22.9M | $35.2M | $18.9M |
| Total Assets | $178.1M | $135.4M | $50.0M | $60.4M | $29.8M |
| Current Liabilities | $15.8M | $38.7M | $17.8M | $11.9M | $7.8M |
| Long-Term Debt | $9.4M | $9.7M | $8.9M | $8.9M | $0 |
| Total Liabilities | $25.9M | $52.6M | $30.3M | $28.1M | $11.5M |
| Total Equity | $152.3M | $82.8M | $19.7M | $32.3M | $18.3M |
| Retained Earnings | -$81.8M | -$163.6M | -$256.8M | -$294.6M | -$317.3M |
Cash Flow (Annual)
Last updated: Jun 24, 2026 5:24am (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$15.6M | -$47.5M | -$88.0M | -$21.7M | -$30.0M |
| Capital Expenditure | $-376,649 | $-733,052 | $-665,700 | $-158,322 | $-1,083 |
| Free Cash Flow | -$15.9M | -$48.2M | -$88.7M | -$21.8M | -$30.0M |
| Acquisitions (net) | $15.0M | $5.0M | $0 | $0 | $24.8M |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $108.8M | -$42.2M | -$70.6M | $15.3M | -$9.1M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 5:46am (4h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$4.0M $2.8M – $5.6M
|
$50.0M $35.6M – $69.6M
|
$125.0M $88.9M – $174.1M
|
$0 |
| EBITDA |
-$1.5M -$2.1M – -$1.0M
|
-$18.4M -$25.6M – -$13.1M
|
-$46.0M -$64.1M – -$32.7M
|
$0 |
| Net Income |
-$15.4M -$21.8M – -$9.0M
|
-$9.7M -$12.5M – -$6.9M
|
-$11.2M -$16.9M – -$7.0M
|
-$10.6M -$16.0M – -$6.6M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 24, 2026 5:24am (3d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -35.8% | -58.6% | +3.6% | -100.0% |
| Gross Profit Growth | -36.2% | -75.3% | -22.6% | -102.6% |
| Operating Income Growth | -741.5% | -12.7% | +60.6% | +33.0% |
| Net Income Growth | -1,233.0% | -11.2% | +59.4% | +39.9% |
| EBITDA Growth | -913.0% | -13.6% | +59.8% | +2.3% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 5:46am (4h ago)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-05-04 | STEINER MITCHELL SHUSTER | A-Award | 604,000.00 | $2.25 | $1.4M |
| 2026-05-04 | Greco Michele | A-Award | 164,000.00 | $2.25 | $369,000 |
| 2026-05-04 | Katzovitz Loren Mark | A-Award | 102,000.00 | $2.25 | $229,500 |
| 2026-05-04 | Hyun Grace | A-Award | 97,000.00 | $2.25 | $218,250 |
| 2026-05-04 | Rankowitz Michael L | A-Award | 100,000.00 | $2.25 | $225,000 |
| 2026-05-04 | Lu Lucy | A-Award | 104,000.00 | $2.25 | $234,000 |
| 2026-05-04 | BARNETTE K GARY | A-Award | 160,000.00 | $2.25 | $360,000 |
| 2026-05-04 | FISCH HARRY | A-Award | 160,000.00 | $2.25 | $360,000 |
| 2025-12-05 | BARNETTE K GARY | A-Award | 27,000.00 | $2.49 | $67,230 |
| 2025-12-05 | Rankowitz Michael L | A-Award | 3,000.00 | $2.49 | $7,470 |
| 2025-12-05 | Katzovitz Loren Mark | A-Award | 6,000.00 | $2.49 | $14,940 |
| 2025-12-05 | STEINER MITCHELL SHUSTER | A-Award | 100,000.00 | $2.49 | $249,000 |
| 2025-12-05 | Hyun Grace | A-Award | 6,000.00 | $2.49 | $14,940 |
| 2025-12-05 | Greco Michele | A-Award | 27,000.00 | $2.49 | $67,230 |
| 2025-12-05 | Lu Lucy | A-Award | 4,000.00 | $2.49 | $9,960 |
| 2025-12-05 | FISCH HARRY | A-Award | 27,000.00 | $2.49 | $67,230 |
| 2025-10-01 | Rankowitz Michael L | A-Award | 7,000.00 | $3.89 | $27,230 |
| 2025-10-01 | Hyun Grace | A-Award | 3,000.00 | $3.89 | $11,670 |
| 2025-10-01 | Lu Lucy | A-Award | 6,000.00 | $3.89 | $23,340 |
| 2025-05-06 | Hyun Grace | A-Award | 55,000.00 | $0.50 | $27,616 |
Dividend History (Last 20)
Last updated: Jun 24, 2026 5:24am (3d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2014-04-28 | $0.07 | 2014-03-24 | 2014-04-30 | 2014-05-07 |
| 2014-01-27 | $0.07 | 2013-12-16 | 2014-01-29 | 2014-02-05 |
| 2013-10-28 | $0.07 | 2013-10-04 | 2013-10-30 | 2013-11-06 |
| 2013-07-29 | $0.07 | 2013-07-15 | 2013-07-31 | 2013-08-07 |
| 2013-04-29 | $0.07 | 2013-03-27 | 2013-05-01 | 2013-05-08 |
| 2013-01-28 | $0.06 | 2013-01-03 | 2013-01-30 | 2013-02-06 |
| 2012-10-29 | $0.06 | 2012-10-05 | 2012-10-31 | 2012-11-07 |
| 2012-07-30 | $0.06 | 2012-07-13 | 2012-08-01 | 2012-08-08 |
| 2012-04-30 | $0.06 | 2012-03-27 | 2012-05-02 | 2012-05-09 |
| 2012-01-30 | $0.05 | 2012-01-05 | 2012-02-01 | 2012-02-09 |
| 2011-10-31 | $0.05 | 2011-10-07 | 2011-11-02 | 2011-11-09 |
| 2011-07-29 | $0.05 | 2011-07-14 | 2011-08-02 | 2011-08-09 |
| 2011-04-29 | $0.05 | 2011-04-13 | 2011-05-03 | 2011-05-10 |
| 2011-01-27 | $0.05 | 2011-01-14 | 2011-01-31 | 2011-02-07 |
| 2010-11-01 | $0.05 | 2010-10-08 | 2010-11-03 | 2010-11-10 |
| 2010-08-02 | $0.05 | 2010-07-22 | 2010-08-04 | 2010-08-11 |
| 2010-04-21 | $0.05 | 2010-04-12 | 2010-04-23 | 2010-05-12 |
| 2010-01-27 | $0.05 | 2010-01-19 | 2010-01-29 | 2010-02-16 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for VERU — it's generated by the pipeline (
market-narrative step).
No community reviews yet for VERU.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30